Brief: Atea Pharmaceuticals Completes Patient Enrollment In North American Phase 3 Trial Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
22/12/2025 12:02
Dec 22 (Reuters) - Atea Pharmaceuticals Inc AVIR.O: ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN NORTH AMERICAN PHASE 3 TRIAL EVALUATING REGIMEN OF BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS ATEA PHARMACEUTICALS INC - C-BEYOND TOPLINE RESULTS EXPECTED MID-2026 ATEA PHARMACEUTICALS INC - C-FORWARD PHASE 3 TRIAL TOPLINE RESULTS ANTICIPATED YEAR-END 2026 Source text: ID:nGNX8j8m52 Further company coverage: AVIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM